Alnylam Becomes Newest Partner in FinnGen Consortium

FinnGen is proud to welcome Alnylam Pharmaceuticals as its newest industry partner. As the 15th pharmaceutical company to join the public-private partnership, Alnylam brings world-leading expertise in RNA interference (RNAi) therapeutics to the consortium, further enriching the scientific and translational potential of the FinnGen study.
The image features the FinnGen logo on a purple background, the Alnylam Pharmaceuticals logo in the center, and a blue heart-shaped sign with the word “WELCOME” on the right.

Founded in 2002, Alnylam is a pioneer in harnessing RNAi to develop innovative medicines for patients with rare and prevalent diseases. With a strong commitment to using genetic research to develop transformative medicines, Alnylam’s participation in FinnGen marks a significant step toward expanding the study’s reach into novel therapeutic areas.

"We are excited to collaborate with FinnGen to uncover genetic insights that inform our therapeutic development strategy," said Paul Nioi, Senior Vice President of Research at Alnylam. “This important alliance will help enable novel target discoveries and fuel the expansion of RNAi therapeutics to treat more diseases."

The FinnGen study, launched in 2017, aims to improve human health through genetic research by combining genome information with national health registry data from Finnish biobank participants. The study is a unique collaboration between Finnish academic and biobank organizations and international pharmaceutical companies.

FinnGen, which is now in its ninth year, has successfully enrolled over 500,000 participants, making it one of the largest and most comprehensive biobank-based genetic research projects in the world. By leveraging Finland’s unique population structure and robust health data infrastructure, FinnGen continues to generate scientific insights that have global relevance for precision medicine.

“We are pleased to welcome Alnylam as a new partner in the FinnGen consortium,” says Professor Aarno Palotie, Scientific Director of FinnGen. “Alnylam’s pioneering leadership in RNA interference therapeutics adds significant scientific depth to the collaboration. Broadening the FinnGen knowledge base enhances our collective capacity to leverage biobank-based research for the advancement and acceleration of novel therapeutic development.”

With Alnylam’s addition, FinnGen continues to grow as one of the world’s leading genomic research initiatives, fostering collaboration across disciplines and borders to unlock the full potential of genetic data.